What is Retatrutide? The Triple-Agonist Peptide Researchers Are Watching
Written by Elyte Peptides Research Team
Retatrutide (GLP3-R) is a novel triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors. Learn about its mechanism of action, research findings, and how it compares to other GLP-1 peptides.
Understanding Retatrutide: A New Frontier in Peptide Research
Retatrutide, also designated as LY3437943 or GLP3-R, has emerged as one of the most closely watched peptides in metabolic research. Unlike earlier single- or dual-agonist compounds, Retatrutide activates three distinct receptors simultaneously — making it the first triple-agonist peptide to reach advanced clinical investigation.
For laboratory researchers studying weight management pathways, Retatrutide represents a significant evolution in how multi-receptor targeting can amplify metabolic signaling.
Mechanism of Action: Three Receptors, One Peptide
Retatrutide’s defining characteristic is its simultaneous agonism of three receptors:
- GLP-1 (glucagon-like peptide-1) receptor — Slows gastric emptying and modulates appetite-related signaling in preclinical models. This is the same receptor targeted by semaglutide and liraglutide.
- GIP (glucose-dependent insulinotropic polypeptide) receptor — Enhances incretin signaling and may support improved lipid metabolism. Tirzepatide targets both GIP and GLP-1, but not glucagon.
- Glucagon receptor — The third and novel target. Glucagon receptor activation has been shown to increase energy expenditure and promote hepatic lipid oxidation in animal models.
This triple mechanism distinguishes Retatrutide from dual-agonist compounds like tirzepatide (GIP/GLP-1) and positions it as a uniquely broad-spectrum tool for metabolic pathway research.
Key Research Findings
Phase 2 Clinical Data
Published results from a 48-week Phase 2 trial (Jastreboff et al., NEJM, 2023) reported notable outcomes in participants receiving Retatrutide across multiple dose cohorts:
- The highest-dose cohort demonstrated a mean body weight reduction of approximately 24.2% at 48 weeks.
- Dose-dependent responses were observed across all cohorts, with statistically significant separation from placebo.
- Metabolic biomarkers, including HbA1c and fasting glucose, showed meaningful changes in cohorts with concurrent type 2 diabetes.
Hepatic and Lipid Research
Emerging preclinical data suggests that the glucagon receptor component may contribute to reductions in hepatic fat content. Phase 2 sub-studies observed notable decreases in liver fat percentage, raising interest in Retatrutide’s potential applications in MASLD (metabolic dysfunction-associated steatotic liver disease) research.
Ongoing Trials
As of 2026, Retatrutide remains under investigation in multiple Phase 3 trials. Researchers are examining its effects across a range of metabolic endpoints, including body composition changes, cardiovascular biomarkers, and hepatic outcomes.
How Retatrutide Compares to Other GLP-1 Peptides
| Compound | Receptor Targets | Mechanism |
|---|---|---|
| Semaglutide | GLP-1 | Single agonist |
| Tirzepatide | GIP + GLP-1 | Dual agonist |
| Retatrutide | GIP + GLP-1 + Glucagon | Triple agonist |
| Cagrilintide | Amylin | Amylin analog |
| CagriSema | Amylin + GLP-1 | Combination therapy |
The addition of glucagon receptor activation is the key differentiator. In preclinical models, glucagon signaling increases resting energy expenditure — a mechanism absent from GLP-1-only or GIP/GLP-1 compounds.
Handling and Storage for Laboratory Use
Researchers working with Retatrutide should follow standard peptide handling protocols:
- Storage: Store lyophilized peptide at -20C or below. Avoid repeated freeze-thaw cycles.
- Reconstitution: Reconstitute with bacteriostatic water. Direct the stream along the vial wall — do not inject directly into the powder. Allow the peptide to dissolve gently without vortexing.
- Post-reconstitution storage: Refrigerate at 2-8C. Use within 30 days for optimal stability.
- Light sensitivity: Keep reconstituted solution away from direct light.
For a detailed walkthrough of peptide reconstitution, see our reconstitution guide.
Why Researchers Are Watching Retatrutide
The triple-agonist approach represents a paradigm shift in metabolic peptide research. By engaging three complementary receptor systems, Retatrutide opens new lines of inquiry into energy expenditure, appetite regulation, and hepatic metabolism that single- or dual-agonist tools cannot fully address.
As Phase 3 data matures through 2026 and beyond, Retatrutide is positioned to become a cornerstone reference compound for laboratories studying multi-receptor metabolic pathways.
Ready to add Retatrutide to your research? Browse our Retatrutide (GLP3-R) product page for purity data, COAs, and ordering information.
For research use only. Not for human consumption.